Biogen · 13 hours ago
Intern, Quality Control Raw Materials
Biogen is a mid-sized biotechnology company committed to delivering life-changing medicines. They are seeking an intern for the Quality Control Raw Materials team, responsible for ensuring that all materials needed for manufacturing are inspected, sampled, tested, and released to meet manufacturing timelines.
BiotechnologyHealth CareNeuroscienceTherapeutics
Responsibilities
Train on basic laboratory techniques and procedures assigned
Train on identification testing as well as compendial testing for materials
Learn how to use KNEAT, LIMS, and Oracle enterprise systems
Participate in team meetings
Supporting QC to reduce/streamline sample submissions to Contract Lab Organizations (CLOs) and the receipt of data to reduce turnaround times (TAT) and release of materials
Learn basic identification techniques and compendial testing
Qualification
Required
Legal authorization to work in the U.S
At least 18 years of age prior to the scheduled start date
Currently enrolled in an accredited community college, college, university or skills program/apprenticeship
Seeking rising juniors and seniors, pursuing a bachelor's degree in a scientific field
Conscientious self-starter with good attention to detail
Ability to multi-task and balance multiple projects
Strong communication skills
Demonstrates flexibility and willingness to learn
Benefits
Company paid holidays
Commuter benefits
Employee Resource Groups participation
80 hours of sick time per calendar year
Company
Biogen
Biogen is an American biotechnology company that provides therapeutics for neurological, autoimmune, and rare diseases.
H1B Sponsorship
Biogen has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (100)
2024 (93)
2023 (101)
2022 (134)
2021 (104)
2020 (114)
Funding
Current Stage
Public CompanyTotal Funding
$1.5BKey Investors
JP Morgan
2023-08-28Post Ipo Debt· $1.5B
1991-09-27IPO
Leadership Team
Recent News
2026-01-13
2026-01-13
2026-01-13
Company data provided by crunchbase